CDKN2A and Familial adenomatous polyposis: For instance, one can easily envision the increase in quality of life in patients with familial adenomatous polyposis or somatic BRCA1 and 2 mutations where localized treatment leads to increased p16Ink4a activity, as seen in the naked mole rat, and thus prevents tumour formation.